Stress and addiction: Contribution of the corticotropin releasing factor (CRF) system in neuroplasticity

Frontiers in Molecular Neuroscience

Volumn , Issue AUG 2012, 2012, Pages 1-31

  Haass Koffler, Carolina L ^a,c   Bartlett, Selena E ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN FRANCISCO   (United States)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Addiction; Anxiety; Corticotropin releasing factor system; Ethanol; Neuroplasticity; Stress induced

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR BINDING PROTEIN; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; HORMONE BINDING PROTEIN; UNCLASSIFIED DRUG;

AMYGDALOID NUCLEUS; ANXIETY; ARTICLE; BASOLATERAL AMYGDALA; CENTRAL NUCLEUS (AMYGDALA); DOPAMINERGIC NERVE CELL; DRUG DEPENDENCE; DRUG SEEKING BEHAVIOR; DRUG WITHDRAWAL; EMOTIONAL DISORDER; EXTENDED AMYGDALA; HUMAN; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NEGATIVE REINFORCEMENT; NERVE CELL PLASTICITY; NEUROTRANSMISSION; NONHUMAN; NUCLEUS ACCUMBENS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; REINFORCEMENT; STRESS; STRESS INDUCED DRUG DEPENDENCE; SUBSTANCE ABUSE; VENTRAL TEGMENTUM; ADAPTATION; ADDICTION; BEHAVIOR CHANGE; BRAIN REGION; DRUG ABUSE; MENTAL DISEASE; RELAPSE; REVIEW; WITHDRAWAL SYNDROME;

EID: 84865968721     PISSN: 16625099     EISSN: None     Source Type: Journal    
DOI: 10.3389/fnmol.2012.00091     Document Type: Article

References (218)

1. Adolphs R, Tranel D, Damasio H and Damasio A (1994) Impaired recognition of emotion in facial expressions following bilateral damage to the human amygdala. Nature 372(6507):669-672.
2. Ambrosio E, Sharpe LG and Pilotte NS (1997) Regional binding to corticotrophin releasing factor receptors in brain of rats exposed to chronic cocaine and cocaine withdrawal. Synapse 25(3):272-276.
3. Arborelius L, Owens MJ, Plotsky PM and Nemeroff CB (1999) The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol 160(1):1-12.
4. Bajo M, Cruz MT, Siggins GR, Messing R and Roberto M (2008) Protein kinase C epsilon mediation of CRF- and ethanol-induced GABA release in central amygdala. Proc Natl Acad Sci U S A 105(24):8410-8415.
5. Baldwin HA, Rassnick S, Rivier J, Koob GF and Britton KT (1991) CRF antagonist reverses the anxiogenic response to ethanol withdrawal in the rat. Psychopharmacology (Berl) 103(2):227-232.
6. Bale TL, Contarino A, Smith GW, Chan R, Gold LH, Sawchenko PE, Koob GF, Vale WW and Lee KF (2000) Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nat Genet 24(4):410-414.
7. Bale TL, Lee KF and Vale WW (2002) The role of corticotropin-releasing factor receptors in stress and anxiety. Integr Comp Biol 42(3):552-555.
8. Bale TL and Vale WW (2004) CRF and CRF receptors: role in stress responsivity and other behaviors. Annu Rev Pharmacol Toxicol 44:525-557.
9. Balleine BW and Killcross S (2006) Parallel incentive processing: an integrated view of amygdala function. Trends Neurosci 29(5):272-279.
10. Beckstead MJ, Gantz SC, Ford CP, Stenzel-Poore MP, Phillips PE, Mark GP and Williams JT (2009) CRF enhancement of GIRK channel-mediated transmission in dopamine neurons. Neuropsychopharmacology 34(8):1926-1935.
11. Behan DP, De Souza EB, Lowry PJ, Potter E, Sawchenko P and Vale WW (1995a) Corticotropin releasing factor (CRF) binding protein: a novel regulator of CRF and related peptides. Front Neuroendocrinol 16(4):362-382.
12. Behan DP, Maciejewski D, Chalmers D and De Souza EB (1995b) Corticotropin releasing factor binding protein (CRF-BP) is expressed in neuronal and astrocytic cells. Brain Res 698(1-2):259-264.
13. Berridge KC and Robinson TE (1998) What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Brain Res Rev 28(3):309-369.
14. Berridge KC, Venier IL and Robinson TE (1989) Taste reactivity analysis of 6hydroxydopamine-induced aphagia: implications for arousal and anhedonia hypotheses of dopamine function. Behav Neurosci 103(1):36-45.
15. Bjork K, Hansson AC and Sommer WH (2010) Genetic variation and brain gene expression in rodent models of alcoholism implications for medication development. Int Rev Neurobiol 91:129-171.
16. Blanco EH, Zuniga JP, Andres ME, Alvarez AR and Gysling K (2011) Corticotropin-releasing factor binding protein enters the regulated secretory pathway in neuroendocrine cells and cortical neurons. Neuropeptides 45(4):273-279.
17. Bonci A and Borgland S (2009) Role of orexin/hypocretin and CRF in the formation of drug-dependent synaptic plasticity in the mesolimbic system. Neuropharmacology 56 Suppl 1:107-111.
18. Bonci A and Malenka RC (1999) Properties and plasticity of excitatory synapses on dopaminergic and GABAergic cells in the ventral tegmental area. J Neurosci 19(10):3723-3730.
19. Borgland SL, Ungless MA and Bonci (2010) A Convergent actions of orexin/hypocretin and CRF on dopamine neurons: Emerging players in addiction. Brain Res 1314:139-144.
20. Britton DR, Koob GF, Rivier J and Vale W (1982) Intraventricular corticotropin-releasing factor enhances behavioral effects of novelty. Life Sci 31(4):363-367.
21. Buczek Y, Le AD, Wang A, Stewart J and Shaham Y (1999) Stress reinstates nicotine seeking but not sucrose solution seeking in rats. Psychopharmacology (Berl) 144(2):183-188.
22. Burnett JC, Jr. (2005) Urocortin: advancing the neurohumoral hypothesis of heart failure. Circulation 112(23):3544-3546.
23. Cador M, Cole BJ, Koob GF, Stinus L and Le Moal M (1993) Central administration of corticotropin releasing factor induces long-term sensitization to D-amphetamine. Brain Res 606(2):181-186.
24. Carboni E, Silvagni A, Rolando MT and Di Chiara G (2000) Stimulation of in vivo dopamine transmission in the bed nucleus of stria terminalis by reinforcing drugs. J Neurosci 20(20):RC102.
25. Chang CP, Pearse RV, 2nd, O'Connell S and Rosenfeld MG (1993) Identification of a seven transmembrane helix receptor for corticotropin-releasing factor and sauvagine in mammalian brain. Neuron 11(6):1187-1195.
26. Chen A, Zorrilla E, Smith S, Rousso D, Levy C, Vaughan J, Donaldson C, Roberts A, Lee KF and Vale W (2006) Urocortin 2-deficient mice exhibit gender-specific alterations in circadian hypothalamus-pituitary-adrenal axis and depressive-like behavior. J Neurosci 26(20):5500-5510.
27. Chen R, Lewis KA, Perrin MH and Vale WW (1993) Expression cloning of a human corticotropin-releasing-factor receptor. Proc Natl Acad Sci U S A 90(19):8967-8971.
28. Choi DS, Wang D, Dadgar J, Chang WS and Messing RO (2002) Conditional rescue of protein kinase C epsilon regulates ethanol preference and hypnotic sensitivity in adult mice. J Neurosci 22(22):9905-9911.
29. Christian DT, Alexander NJ, Diaz MR, Robinson S and McCool BA (2012) Chronic intermittent ethanol and withdrawal differentially modulate basolateral amygdala AMPA-type glutamate receptor function and trafficking. Neuropharmacology 62(7):2429-2438.
30. Chu K, Koob GF, Cole M, Zorrilla EP and Roberts AJ (2007) Dependence-induced increases in ethanol self-administration in mice are blocked by the CRF1 receptor antagonist antalarmin and by CRF1 receptor knockout. Pharmacol Biochem Behav 86(4):813-821.
31. Cole BJ, Cador M, Stinus L, Rivier J, Vale W, Koob GF and Le Moal M (1990) Central administration of a CRF antagonist blocks the development of stress-induced behavioral sensitization. Brain Res 512(2):343-346.
32. Coste SC, Kesterson RA, Heldwein KA, Stevens SL, Heard AD, Hollis JH, Murray SE, Hill JK, Pantely GA, Hohimer AR, Hatton DC, Phillips TJ, Finn DA, Low MJ, Rittenberg MB, Stenzel P and Stenzel-Poore MP (2000) Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2. Nat Genet 24(4):403-409.
33. David V, Matifas A, Gavello-Baudy S, Decorte L, Kieffer BL and Cazala P (2008) Brain regional Fos expression elicited by the activation of mu- but not delta-opioid receptors of the ventral tegmental area: evidence for an implication of the ventral thalamus in opiate reward. Neuropsychopharmacology 33(7):1746-1759.
34. Davis LL, Trivedi M, Choate A, Kramer GL and Petty F (1997) Growth hormone response to the GABAB agonist baclofen in major depressive disorder. Psychoneuroendocrinology 22(3):129-140.
35. Davis M (1992a) The role of the amygdala in fear-potentiated startle: implications for animal models of anxiety. Trends Pharmacol Sci 13(1):35-41.
36. Davis M (1992b) The role of the amygdala in fear and anxiety. Annu Rev Neurosci 15:353-375.
37. Davis M and Shi C (2000) The amygdala. Curr Biol 10(4):R131.
38. Davis M and Whalen PJ (2001) The amygdala: vigilance and emotion. Mol Psychiatry 6(1):13-34.
39. Day HE, Curran EJ, Watson SJ, Jr. and Akil H (1999) Distinct neurochemical populations in the rat central nucleus of the amygdala and bed nucleus of the stria terminalis: evidence for their selective activation by interleukin-1beta. J Comp Neurol 413(1):113-128.
40. De Souza EB (1995) Corticotropin-releasing factor receptors: physiology, pharmacology, biochemistry and role in central nervous system and immune disorders. Psychoneuroendocrinology 20(8):789-819.
41. Diana M (2011) The dopamine hypothesis of drug addiction and its potential therapeutic value. Front Psychiatry 2:64.
42. Eiler WJ, 2nd, Seyoum R, Foster KL, Mailey C and June HL (2003) D1 dopamine receptor regulates alcohol-motivated behaviors in the bed nucleus of the stria terminalis in alcohol-preferring (P) rats. Synapse 48(1):45-56.
43. Erb S, Shaham Y and Stewart J (1996) Stress reinstates cocaine-seeking behavior after prolonged extinction and a drug-free period. Psychopharmacology (Berl) 128(4):408-412.
44. Everitt BJ, Parkinson JA, Olmstead MC, Arroyo M, Robledo P and Robbins TW (1999) Associative processes in addiction and reward. The role of amygdala-ventral striatal subsystems. Ann N Y Acad Sci 877:412-438.
45. Everitt BJ and Robbins TW (2005) Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat Neurosci 8(11):1481-1489.
46. Feltenstein MW and See RE (2008) The neurocircuitry of addiction: an overview. Br J Pharmacol 154(2):261-274.
47. Fibiger HC (1978) Drugs and reinforcement mechanisms: a critical review of the catecholamine theory. Annu Rev Pharmacol Toxicol 18:37-56.
48. Francesconi W, Berton F, Repunte-Canonigo V, Hagihara K, Thurbon D, Lekic D, Specio SE, Greenwell TN, Chen SA, Rice KC, Richardson HN, O'Dell LE, Zorrilla EP, Morales M, Koob GF and Sanna PP (2009) Protracted withdrawal from alcohol and drugs of abuse impairs long-term potentiation of intrinsic excitability in the juxtacapsular bed nucleus of the stria terminalis. J Neurosci 29(17):5389-5401.
49. Frye GD and Breese GR (1982) GABAergic modulation of ethanol-induced motor impairment. J Pharmacol Exp Ther 223(3):750-756.
50. Fu Y, Pollandt S, Liu J, Krishnan B, Genzer K, Orozco-Cabal L, Gallagher JP and Shinnick-Gallagher P (2007) Long-term potentiation (LTP) in the central amygdala (CeA) is enhanced after prolonged withdrawal from chronic cocaine and requires CRF1 receptors. J Neurophysiol 97(1):937-941.
51. Fudge JL and Emiliano AB (2003) The extended amygdala and the dopamine system: another piece of the dopamine puzzle. J Neuropsychiatry Clin Neurosci 15(3):306-316.
52. Funk CK, Zorrilla EP, Lee MJ, Rice KC and Koob GF (2007) Corticotropin-releasing factor 1 antagonists selectively reduce ethanol self-administration in ethanol-dependent rats. Biol Psychiatry 61(1):78-86.
53. Funk D, Li Z and Le AD (2006) Effects of environmental and pharmacological stressors on c-fos and corticotropin-releasing factor mRNA in rat brain: Relationship to the reinstatement of alcohol seeking. Neuroscience 138(1):235-243.
54. Gass JT and Olive MF (2007) Reinstatement of ethanol-seeking behavior following intravenous self-administration in Wistar rats. Alcohol Clin Exp Res 31(9):1441-1445.
55. Gatto GJ, McBride WJ, Murphy JM, Lumeng L and Li TK (1994) Ethanol self-infusion into the ventral tegmental area by alcohol-preferring rats. Alcohol 11(6):557-564.
56. Gawin FH and Kleber HD (1986) Abstinence symptomatology and psychiatric diagnosis in cocaine abusers. Clinical observations. Arch Gen Psychiatry 43(2):107-113.
57. Gehlert DR, Cippitelli A, Thorsell A, Le AD, Hipskind PA, Hamdouchi C, Lu J, Hembre EJ, Cramer J, Song M, McKinzie D, Morin M, Ciccocioppo R and Heilig M (2007) 3-(4-Chloro-2-morpholin-4-yl-thiazol-5-yl)-8-(1-ethylpropyl)-2,6dimethyl-imidazo [1,2-b]pyridazine: a novel brain-penetrant, orally available corticotropin-releasing factor receptor 1 antagonist with efficacy in animal models of alcoholism. J Neurosci 27(10):2718-2726.
58. Gehlert DR, Cramer J and Morin SM (2012) Effects of corticotropin-releasing factor 1 receptor antagonism on the hypothalamic-pituitary-adrenal axis of rodents. J Pharmacol Exp Ther 341(3):672-680.
59. George O, Le Moal M and Koob GF (2011) Allostasis and addiction: role of the dopamine and corticotropin-releasing factor systems. Physiol Behav 106(1):58-64.
60. Georges F and Aston-Jones G (2001) Potent regulation of midbrain dopamine neurons by the bed nucleus of the stria terminalis. J Neurosci 21(16):RC160.
61. Georges F and Aston-Jones G (2002) Activation of ventral tegmental area cells by the bed nucleus of the stria terminalis: a novel excitatory amino acid input to midbrain dopamine neurons. J Neurosci 22(12):5173-5187.
62. Ghitza UE, Gray SM, Epstein DH, Rice KC and Shaham Y (2006) The anxiogenic drug yohimbine reinstates palatable food seeking in a rat relapse model: a role of CRF1 receptors. Neuropsychopharmacology 31(10):2188-2196.
63. Goeders NE and Guerin GF (1994) Non-contingent electric footshock facilitates the acquisition of intravenous cocaine self-administration in rats. Psychopharmacology (Berl) 114(1):63-70.
64. Grace CR, Perrin MH, DiGruccio MR, Miller CL, Rivier JE, Vale WW and Riek R (2004) NMR structure and peptide hormone binding site of the first extracellular domain of a type B1 G protein-coupled receptor. Proc Natl Acad Sci U S A 101(35):12836-12841.
65. Grace CR, Perrin MH, Gulyas J, Digruccio MR, Cantle JP, Rivier JE, Vale WW and Riek R (2007) Structure of the N-terminal domain of a type B1 G protein-coupled receptor in complex with a peptide ligand. Proc Natl Acad Sci U S A 104(12):4858-4863.
66. Guillemin R and Rosenberg B (1955) Humoral hypothalamic control of anterior pituitary: a study with combined tissue cultures. Endocrinology 57(5):599-607.
67. Hahn J, Hopf FW and Bonci A (2009) Chronic cocaine enhances corticotropin-releasing factor-dependent potentiation of excitatory transmission in ventral tegmental area dopamine neurons. J Neurosci 29(20):6535-6544.
68. Hansson AC, Cippitelli A, Sommer WH, Ciccocioppo R and Heilig M (2007) Region-specific down-regulation of Crhr1 gene expression in alcohol-preferring msP rats following ad lib access to alcohol. Addict Biol 12(1):30-34.
69. Hansson AC, Cippitelli A, Sommer WH, Fedeli A, Bjork K, Soverchia L, Terasmaa A, Massi M, Heilig M and Ciccocioppo R (2006) Variation at the rat Crhr1 locus and sensitivity to relapse into alcohol seeking induced by environmental stress. Proc Natl Acad Sci U S A 103(41):15236-15241.
70. Hansson AC, Rimondini R, Neznanova O, Sommer WH and Heilig M (2008) Neuroplasticity in brain reward circuitry following a history of ethanol dependence. Eur J Neurosci 27(8):1912-1922.
71. Heilig M and Koob GF (2007) A key role for corticotropin-releasing factor in alcohol dependence. Trends Neurosci 30(8):399-406.
72. Heilig M, Thorsell A, Sommer WH, Hansson AC, Ramchandani VA, George DT, Hommer D and Barr CS (2010) Translating the neuroscience of alcoholism into clinical treatments: from blocking the buzz to curing the blues. Neurosci Biobehav Rev 35(2):334-344.
73. Heimer L and Alheid GF (1991) Piecing together the puzzle of basal forebrain anatomy. Adv Exp Med Biol 295:1-42.
74. Heinrichs SC, Menzaghi F, Schulteis G, Koob GF and Stinus L (1995) Suppression of corticotropin-releasing factor in the amygdala attenuates aversive consequences of morphine withdrawal. Behav Pharmacol 6(1):74-80.
75. Heinrichs SC, Pich EM, Miczek KA, Britton KT and Koob GF (1992) Corticotropin-releasing factor antagonist reduces emotionality in socially defeated rats via direct neurotropic action. Brain Res 581(2):190-197.
76. Herringa RJ, Nanda SA, Hsu DT, Roseboom PH and Kalin NH (2004) The effects of acute stress on the regulation of central and basolateral amygdala CRF-binding protein gene expression. Brain Res Mol Brain Res 131(1-2):17-25.
77. Hoare SR (2005) Mechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors. Drug Discov Today 10(6):417-427.
78. Hodge CW, Raber J, McMahon T, Walter H, Sanchez-Perez AM, Olive MF, Mehmert K, Morrow AL and Messing RO (2002) Decreased anxiety-like behavior, reduced stress hormones, and neurosteroid supersensitivity in mice lacking protein kinase Cepsilon. J Clin Invest 110(7):1003-1010.
79. Hsu SY and Hsueh AJ (2001) Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nat Med 7(5):605-611.
80. Hubbard DT, Nakashima BR, Lee I and Takahashi LK (2007) Activation of basolateral amygdala corticotropin-releasing factor 1 receptors modulates the consolidation of contextual fear. Neuroscience 150(4):818-828.
81. Hyytia P and Koob GF (1995) GABAA receptor antagonism in the extended amygdala decreases ethanol self-administration in rats. Eur J Pharmacol 283(1-3):151-159.
82. Jochman KA, Newman SM, Kalin NH and Bakshi VP (2005) Corticotropin-releasing factor-1 receptors in the basolateral amygdala mediate stress-induced anorexia. Behav Neurosci 119(6):1448-1458.
83. Justice NJ, Yuan ZF, Sawchenko PE and Vale W (2008) Type 1 corticotropin-releasing factor receptor expression reported in BAC transgenic mice: implications for reconciling ligand-receptor mismatch in the central corticotropin-releasing factor system. J Comp Neurol 511(4):479-496.
84. Karolyi IJ, Burrows HL, Ramesh TM, Nakajima M, Lesh JS, Seong E, Camper SA and Seasholtz AF (1999) Altered anxiety and weight gain in corticotropin-releasing hormone-binding protein-deficient mice. Proc Natl Acad Sci U S A 96(20):11595-11600.
85. Kash TL, Nobis WP, Matthews RT and Winder DG (2008) Dopamine enhances fast excitatory synaptic transmission in the extended amygdala by a CRF-R1dependent process. J Neurosci 28(51):13856-13865.
86. Kash TL and Winder DG (2006) Neuropeptide Y and corticotropin-releasing factor bidirectionally modulate inhibitory synaptic transmission in the bed nucleus of the stria terminalis. Neuropharmacology 51(5):1013-1022.
87. Kemp CF, Woods RJ and Lowry PJ (1998) The corticotrophin-releasing factor-binding protein: an act of several parts. Peptides 19(6):1119-1128.
88. Kimura Y, Takahashi K, Totsune K, Muramatsu Y, Kaneko C, Darnel AD, Suzuki T, Ebina M, Nukiwa T and Sasano H (2002) Expression of urocortin and corticotropin-releasing factor receptor subtypes in the human heart. J Clin Endocrinol Metab 87(1):340-346.
89. Kishimoto T, Radulovic J, Radulovic M, Lin CR, Schrick C, Hooshmand F, Hermanson O, Rosenfeld MG and Spiess J (2000) Deletion of crhr2 reveals an anxiolytic role for corticotropin-releasing hormone receptor-2. Nat Genet 24(4):415-419.
90. Koob G and Kreek MJ (2007) Stress, dysregulation of drug reward pathways, and the transition to drug dependence. Am J Psychiatry 164(8):1149-1159.
91. Koob GF (1992) Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci 13(5):177-184.
92. Koob GF (1999) Stress, corticotropin-releasing factor, and drug addiction. Ann N Y Acad Sci 897:27-45.
93. Koob GF (2003) Neuroadaptive mechanisms of addiction: studies on the extended amygdala. Eur Neuropsychopharmacol 13(6):442-452.
94. Koob GF (2009a) Dynamics of neuronal circuits in addiction: reward, antireward, and emotional memory. Pharmacopsychiatry 42 Suppl 1:S32-S41.
95. Koob GF (2009b) Neurobiological substrates for the dark side of compulsivity in addiction. Neuropharmacology 56 Suppl 1:18-31.
96. Koob GF, Ahmed SH, Boutrel B, Chen SA, Kenny PJ, Markou A, O'Dell LE, Parsons LH and Sanna PP (2004) Neurobiological mechanisms in the transition from drug use to drug dependence. Neurosci Biobehav Rev 27(8):739-749.
97. Koob GF and Bloom FE (1985) Corticotropin-releasing factor and behavior. Fed Proc 44(1 Pt 2):259-263.
98. Koob GF and Heinrichs SC (1999) A role for corticotropin releasing factor and urocortin in behavioral responses to stressors. Brain Res 848(1-2):141-152.
99. Koob GF and Le Moal M (1997) Drug abuse: hedonic homeostatic dysregulation. Science 278(5335):52-58.
100. Koob GF and Le Moal M (2001) Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 24(2):97-129.
101. Koob GF and Le Moal M (2008a) Addiction and the brain antireward system. Annu Rev Psychol 59:29-53.
102. Koob GF and Le Moal M (2008b) Review. Neurobiological mechanisms for opponent motivational processes in addiction. Philos Trans R Soc Lond B Biol Sci 363(1507):3113-3123.
103. Koob GF and Nestler EJ (1997) The neurobiology of drug addiction. J Neuropsychiatry Clin Neurosci 9(3):482-497.
104. Koob GF and Zorrilla EP (2010) Neurobiological mechanisms of addiction: focus on corticotropin-releasing factor. Curr Opin Investig Drugs 11(1):63-71.
105. Koob GF and Zorrilla EP (2012) Update on corticotropin-releasing factor pharmacotherapy for psychiatric disorders: a revisionist view. Neuropsychopharmacology 37(1):308-309.
106. Korotkova TM, Brown RE, Sergeeva OA, Ponomarenko AA and Haas HL (2006) Effects of arousal- and feeding-related neuropeptides on dopaminergic and GABAergic neurons in the ventral tegmental area of the rat. Eur J Neurosci 23(10):2677-2685.
107. Kostich WA, Chen A, Sperle K and Largent BL (1998) Molecular identification and analysis of a novel human corticotropin-releasing factor (CRF) receptor: the CRF2gamma receptor. Mol Endocrinol 12(8):1077-1085.
108. Kreibich AS, Briand L, Cleck JN, Ecke L, Rice KC and Blendy JA (2009) Stress-induced potentiation of cocaine reward: a role for CRF R1 and CREB. Neuropsychopharmacology 34(12):2609-2617.
109. Lack AK, Floyd DW and McCool BA (2005) Chronic ethanol ingestion modulates proanxiety factors expressed in rat central amygdala. Alcohol 36(2):83-90.
110. Le AD, Harding S, Juzytsch W, Fletcher PJ and Shaham Y (2002) The role of corticotropin-releasing factor in the median raphe nucleus in relapse to alcohol. J Neurosci 22(18):7844-7849.
111. Le AD, Harding S, Juzytsch W, Watchus J, Shalev U and Shaham Y (2000) The role of corticotrophin-releasing factor in stress-induced relapse to alcohol-seeking behavior in rats. Psychopharmacology (Berl) 150(3):317-324.
112. Le AD, Quan B, Juzytch W, Fletcher PJ, Joharchi N and Shaham Y (1998) Reinstatement of alcohol-seeking by priming injections of alcohol and exposure to stress in rats. Psychopharmacology (Berl) 135(2):169-174.
113. LeDoux J (2003) The emotional brain, fear, and the amygdala. Cell Mol Neurobiol 23(45):727-738.
114. LeDoux JE (1992) Brain mechanisms of emotion and emotional learning. Curr Opin Neurobiol 2(2):191-197.
115. LeDoux JE (1993) Emotional memory systems in the brain. Behav Brain Res 58(1-2):69-79.
116. LeDoux JE (2000) Emotion circuits in the brain. Annu Rev Neurosci 23:155-184.
117. Lewis K, Li C, Perrin MH, Blount A, Kunitake K, Donaldson C, Vaughan J, Reyes TM, Gulyas J, Fischer W, Bilezikjian L, Rivier J, Sawchenko PE and Vale WW (2001) Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc Natl Acad Sci U S A 98(13):7570-7575.
118. Li C, Chen P, Vaughan J, Lee KF and Vale W (2007) Urocortin 3 regulates glucose-stimulated insulin secretion and energy homeostasis. Proc Natl Acad Sci U S A 104(10):4206-4211.
119. Liu J, Yu B, Neugebauer V, Grigoriadis DE, Rivier J, Vale WW, Shinnick-Gallagher P and Gallagher JP (2004) Corticotropin-releasing factor and Urocortin I modulate excitatory glutamatergic synaptic transmission. J Neurosci 24(16):4020-4029.
120. Liu X and Weiss F (2002) Additive effect of stress and drug cues on reinstatement of ethanol seeking: exacerbation by history of dependence and role of concurrent activation of corticotropin-releasing factor and opioid mechanisms. J Neurosci 22(18):7856-7861.
121. Logrip ML, Koob GF and Zorrilla EP (2011) Role of corticotropin-releasing factor in drug addiction: potential for pharmacological intervention. CNS Drugs 25(4):271-287.
122. Lovenberg TW, Chalmers DT, Liu C and De Souza EB (1995a) CRF2 alpha and CRF2 beta receptor mRNAs are differentially distributed between the rat central nervous system and peripheral tissues. Endocrinology 136(9):4139-4142.
123. Lovenberg TW, Liaw CW, Grigoriadis DE, Clevenger W, Chalmers DT, De Souza EB and Oltersdorf T (1995b) Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc Natl Acad Sci U S A 92(3):836-840.
124. Lowery-Gionta EG, Navarro M, Li C, Pleil KE, Rinker JA, Cox BR, Sprow GM, Kash TL and Thiele TE (2012) Corticotropin releasing factor signaling in the central amygdala is recruited during binge-like ethanol consumption in C57BL/6J mice. J Neurosci 32(10):3405-3413.
125. Lu L, Shepard JD, Hall FS and Shaham Y (2003) Effect of environmental stressors on opiate and psychostimulant reinforcement, reinstatement and discrimination in rats: a review. Neurosci Biobehav Rev 27(5):457-491.
126. Luscher C and Malenka RC (2011) Drug-evoked synaptic plasticity in addiction: from molecular changes to circuit remodeling. Neuron 69(4):650-663.
127. Maren S (1999) Long-term potentiation in the amygdala: a mechanism for emotional learning and memory. Trends Neurosci 22(12):561-567.
128. Marinelli PW, Funk D, Juzytsch W, Harding S, Rice KC, Shaham Y and Le AD (2007) The CRF1 receptor antagonist antalarmin attenuates yohimbine-induced increases in operant alcohol self-administration and reinstatement of alcohol seeking in rats. Psychopharmacology (Berl) 195(3):345-355.
129. Martin TJ, Coller M, Co C and Smith JE (2008) Micro-opioid receptor alkylation in the ventral pallidum and ventral tegmental area, but not in the nucleus accumbens, attenuates the effects of heroin on cocaine self-administration in rats. Neuropsychopharmacology 33(5):1171-1178.
130. McDonald AJ (1998) Cortical pathways to the mammalian amygdala. Prog Neurobiol 55(3):257-332.
131. Meloni EG, Jackson AV, Cohen BM and Carlezon WA, Jr. (2005) Corticotropin-releasing factor from the rat brain measured by protein immunoblot. Peptides 26(11):2252-2256.
132. Merali Z, McIntosh J, Kent P, Michaud D and Anisman H (1998) Aversive and appetitive events evoke the release of corticotropin-releasing hormone and bombesin-like peptides at the central nucleus of the amygdala. J Neurosci 18(12):4758-4766.
133. Merlo Pich E, Lorang M, Yeganeh M, Rodriguez de Fonseca F, Raber J, Koob GF and Weiss F (1995) Increase of extracellular corticotropin-releasing factor-like immunoreactivity levels in the amygdala of awake rats during restraint stress and ethanol withdrawal as measured by microdialysis. J Neurosci 15(8):5439-5447.
134. Molander A, Vengeliene V, Heilig M, Wurst W, Deussing JM and Spanagel R (2012) Brain-specific inactivation of the Crhr1 gene inhibits post-dependent and stress-induced alcohol intake, but does not affect relapse-like drinking. Neuropsychopharmacology 37(4):1047-1056.
135. Muller MB, Zimmermann S, Sillaber I, Hagemeyer TP, Deussing JM, Timpl P, Kormann MS, Droste SK, Kuhn R, Reul JM, Holsboer F and Wurst W (2003) Limbic corticotropin-releasing hormone receptor 1 mediates anxiety-related behavior and hormonal adaptation to stress. Nat Neurosci 6(10):1100-1107.
136. Nie Z, Schweitzer P, Roberts AJ, Madamba SG, Moore SD and Siggins GR (2004) Ethanol augments GABAergic transmission in the central amygdala via CRF1 receptors. Science 303(5663):1512-1514.
137. Nielsen CK, Simms JA, Bito-Onon JJ, Li R, Ananthan S and Bartlett SE (2011) The delta opioid receptor antagonist, SoRI-9409, decreases yohimbine stress-induced reinstatement of ethanol-seeking. Addict Biol 17(2):224-234.
138. Nielsen SM, Nielsen LZ, Hjorth SA, Perrin MH and Vale WW (2000) Constitutive activation of tethered-peptide/corticotropin-releasing factor receptor chimeras. Proc Natl Acad Sci U S A 97(18):10277-10281.
139. Overstreet DH, Knapp DJ and Breese GR (2004) Modulation of multiple ethanol withdrawal-induced anxiety-like behavior by CRF and CRF1 receptors. Pharmacol Biochem Behav 77(2):405-413.
140. Palkovits M, Brownstein MJ and Vale W (1983) Corticotropin releasing factor (CRF) immunoreactivity in hypothalamic and extrahypothalamic nuclei of sheep brain. Neuroendocrinology 37(4):302-305.
141. Pare D, Quirk GJ and Ledoux JE (2004) New vistas on amygdala networks in conditioned fear. J Neurophysiol 92(1):1-9.
142. Perrin M, Donaldson C, Chen R, Blount A, Berggren T, Bilezikjian L, Sawchenko P and Vale W (1995) Identification of a second corticotropin-releasing factor receptor gene and characterization of a cDNA expressed in heart. Proc Natl Acad Sci U S A 92(7):2969-2973.
143. Phelps EA and LeDoux JE (2005) Contributions of the amygdala to emotion processing: from animal models to human behavior. Neuron 48(2):175-187.
144. Piazza PV, Deminiere JM, le Moal M and Simon H (1990) Stress- and pharmacologically-induced behavioral sensitization increases vulnerability to acquisition of amphetamine self-administration. Brain Res 514(1):22-26.
145. Pierce RC and Kumaresan V (2006) The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse? Neurosci Biobehav Rev 30(2):215-238.
146. Pitkanen A, Jolkkonen E and Kemppainen S (2000) Anatomic heterogeneity of the rat amygdaloid complex. Folia Morphol (Warsz) 59(1):1-23.
147. Pitts MW, Todorovic C, Blank T and Takahashi LK (2009) The central nucleus of the amygdala and corticotropin-releasing factor: insights into contextual fear memory. J Neurosci 29(22):7379-7388.
148. Pollandt S, Liu J, Orozco-Cabal L, Grigoriadis DE, Vale WW, Gallagher JP and Shinnick-Gallagher P (2006) Cocaine withdrawal enhances long-term potentiation induced by corticotropin-releasing factor at central amygdala glutamatergic synapses via CRF, NMDA receptors and PKA. Eur J Neurosci 24(6):1733-1743.
149. Potter E, Behan DP, Linton EA, Lowry PJ, Sawchenko PE and Vale WW (1992) The central distribution of a corticotropin-releasing factor (CRF)-binding protein predicts multiple sites and modes of interaction with CRF. Proc Natl Acad Sci U S A 89(9):4192-4196.
150. Potter E, Sutton S, Donaldson C, Chen R, Perrin M, Lewis K, Sawchenko PE and Vale W (1994) Distribution of corticotropin-releasing factor receptor mRNA expression in the rat brain and pituitary. Proc Natl Acad Sci U S A 91(19):8777-8781.
151. Refojo D, Schweizer M, Kuehne C, Ehrenberg S, Thoeringer C, Vogl AM, Dedic N, Schumacher M, von Wolff G, Avrabos C, Touma C, Engblom D, Schutz G, Nave KA, Eder M, Wotjak CT, Sillaber I, Holsboer F, Wurst W and Deussing JM (2011) Glutamatergic and dopaminergic neurons mediate anxiogenic and anxiolytic effects of CRHR1. Science 333(6051):1903-1907.
152. Reyes TM, Lewis K, Perrin MH, Kunitake KS, Vaughan J, Arias CA, Hogenesch JB, Gulyas J, Rivier J, Vale WW and Sawchenko PE (2001) Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Natl Acad Sci U S A 98(5):2843-2848.
153. Rezayof A, Zarrindast MR, Sahraei H and Haeri-Rohani AH (2002) Involvement of dopamine D2 receptors of the central amygdala on the acquisition and expression of morphine-induced place preference in rat. Pharmacol Biochem Behav 74(1):187-197.
154. Richards JK, Simms JA, Steensland P, Taha SA, Borgland SL, Bonci A and Bartlett SE (2008) Inhibition of orexin-1/hypocretin-1 receptors inhibits yohimbine-induced reinstatement of ethanol and sucrose seeking in Long-Evans rats. Psychopharmacology (Berl) 199(1):109-117.
155. Richter RM, Pich EM, Koob GF and Weiss F (1995) Sensitization of cocaine-stimulated increase in extracellular levels of corticotropin-releasing factor from the rat amygdala after repeated administration as determined by intracranial microdialysis. Neurosci Lett 187(3):169-172.
156. Richter RM and Weiss F (1999) In vivo CRF release in rat amygdala is increased during cocaine withdrawal in self-administering rats. Synapse 32(4):254-261.
157. Rijkers DT, Kruijtzer JA, van Oostenbrugge M, Ronken E, den Hartog JA and Liskamp RM (2004) Structure-activity studies on the corticotropin releasing factor antagonist astressin, leading to a minimal sequence necessary for antagonistic activity. Chembiochem 5(3):340-348.
158. Rivier J, Rivier C and Vale W (1984) Synthetic competitive antagonists of corticotropin-releasing factor: effect on ACTH secretion in the rat. Science 224(4651):889-891.
159. Roberto M, Madamba SG, Moore SD, Tallent MK and Siggins GR (2003) Ethanol increases GABAergic transmission at both pre- and postsynaptic sites in rat central amygdala neurons. Proc Natl Acad Sci U S A 100(4):2053-2058.
160. Roberto M, Madamba SG, Stouffer DG, Parsons LH and Siggins GR (2004) Increased GABA release in the central amygdala of ethanol-dependent rats. J Neurosci 24(45):10159-10166.
161. Roberts AJ, Cole M and Koob GF (1996) Intra-amygdala muscimol decreases operant ethanol self-administration in dependent rats. Alcohol Clin Exp Res 20(7):1289-1298.
162. Rodaros D, Caruana DA, Amir S and Stewart J (2007) Corticotropin-releasing factor projections from limbic forebrain and paraventricular nucleus of the hypothalamus to the region of the ventral tegmental area. Neuroscience 150(1):8-13.
163. Roozendaal B, Brunson KL, Holloway BL, McGaugh JL and Baram TZ (2002) Involvement of stress-released corticotropin-releasing hormone in the basolateral amygdala in regulating memory consolidation. Proc Natl Acad Sci U S A 99(21):13908-13913.
164. Saffran M, Schally AV and Benfey BG (1955) Stimulation of the release of corticotropin from the adenohypophysis by a neurohypophysial factor. Endocrinology 57(4):439-444.
165. Sah P, Faber ES, Lopez De Armentia M and Power J (2003) The amygdaloid complex: anatomy and physiology. Physiol Rev 83(3):803-834.
166. Sakanaka M, Shibasaki T and Lederis K (1986) Distribution and efferent projections of corticotropin-releasing factor-like immunoreactivity in the rat amygdaloid complex. Brain Res 382(2):213-238.
167. Sanchez MM, Young LJ, Plotsky PM and Insel TR (1999) Autoradiographic and in situ hybridization localization of corticotropin-releasing factor 1 and 2 receptors in nonhuman primate brain. J Comp Neurol 408(3):365-377.
168. Sarnyai Z, Hohn J, Szabo G and Penke B (1992) Critical role of endogenous corticotropin-releasing factor (CRF) in the mediation of the behavioral action of cocaine in rats. Life Sci 51(26):2019-2024.
169. Sarnyai Z, Shaham Y and Heinrichs SC (2001) The role of corticotropin-releasing factor in drug addiction. Pharmacol Rev 53(2):209-243.
170. Seasholtz AF, Valverde RA and Denver RJ (2002) Corticotropin-releasing hormone-binding protein: biochemistry and function from fishes to mammals. J Endocrinol 175(1):89-97.
171. Shaham Y, Erb S, Leung S, Buczek Y and Stewart J (1998) CP-154,526, a selective, non-peptide antagonist of the corticotropin-releasing factor1 receptor attenuates stress-induced relapse to drug seeking in cocaine- and heroin-trained rats. Psychopharmacology (Berl) 137(2):184-190.
172. Shaham Y, Funk D, Erb S, Brown TJ, Walker CD and Stewart J (1997) Corticotropin-releasing factor, but not corticosterone, is involved in stress-induced relapse to heroin-seeking in rats. J Neurosci 17(7):2605-2614.
173. Shaham Y, Kelsey JE and Stewart J (1995) Temporal factors in the effect of restraint stress on morphine-induced behavioral sensitization in the rat. Psychopharmacology (Berl) 117(1):102-109.
174. Silberman Y, Bajo M, Chappell AM, Christian DT, Cruz M, Diaz MR, Kash T, Lack AK, Messing RO, Siggins GR, Winder D, Roberto M, McCool BA and Weiner JL (2009) Neurobiological mechanisms contributing to alcohol-stress-anxiety interactions. Alcohol 43(7):509-519.
175. Simms JA, Haass-Koffler CL, Bito-Onon J, Li R and Bartlett SE (2011) Mifepristone in the central nucleus of the amygdala reduces yohimbine stress-induced reinstatement of ethanol-seeking. Neuropsychopharmacology 37(4):906-918.
176. Smith GW, Aubry JM, Dellu F, Contarino A, Bilezikjian LM, Gold LH, Chen R, Marchuk Y, Hauser C, Bentley CA, Sawchenko PE, Koob GF, Vale W and Lee KF (1998) Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron 20(6):1093-1102.
177. Sommer WH, Rimondini R, Hansson AC, Hipskind PA, Gehlert DR, Barr CS and Heilig MA (2008) Upregulation of voluntary alcohol intake, behavioral sensitivity to stress, and amygdala crhr1 expression following a history of dependence. Biol Psychiatry 63(2):139-145.
178. Suda T, Sumitomo T, Tozawa F, Ushiyama T and Demura H (1989) Corticotropin-releasing factor-binding protein is a glycoprotein. Biochem Biophys Res Commun 165(2):703-707.
179. Sun N and Cassell MD (1993) Intrinsic GABAergic neurons in the rat central extended amygdala. J Comp Neurol 330(3):381-404.
180. Swanson LW, Sawchenko PE, Rivier J and Vale WW (1983) Organization of ovine corticotropin-releasing factor immunoreactive cells and fibers in the rat brain: an immunohistochemical study. Neuroendocrinology 36(3):165-186.
181. Tagliaferro P and Morales M (2008) Synapses between corticotropin-releasing factor-containing axon terminals and dopaminergic neurons in the ventral tegmental area are predominantly glutamatergic. J Comp Neurol 506(4):616-626.
182. Thatcher-Britton K and Koob GF (1986) Alcohol reverses the proconflict effect of corticotropin-releasing factor. Regul Pept 16(3-4):315-320.
183. Timpl P, Spanagel R, Sillaber I, Kresse A, Reul JM, Stalla GK, Blanquet V, Steckler T, Holsboer F and Wurst W (1998) Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nat Genet 19(2):162-166.
184. Tomkins DM and Sellers EM (2001) Addiction and the brain: the role of neurotransmitters in the cause and treatment of drug dependence. CMAJ 164(6):817-821.
185. Tronche F, Kellendonk C, Kretz O, Gass P, Anlag K, Orban PC, Bock R, Klein R and Schutz G (1999) Disruption of the glucocorticoid receptor gene in the nervous system results in reduced anxiety. Nat Genet 23(1):99-103.
186. Tsai-Morris CH, Buczko E, Geng Y, Gamboa-Pinto A and Dufau ML (1996) The genomic structure of the rat corticotropin releasing factor receptor. A member of the class II G protein-coupled receptors. J Biol Chem 271(24):14519-14525.
187. Turnbull AV and Rivier C (1997) Corticotropin-releasing factor (CRF) and endocrine responses to stress: CRF receptors, binding protein, and related peptides. Proc Soc Exp Biol Med 215(1):1-10.
188. Tye KM, Stuber GD, de Ridder B, Bonci A and Janak PH (2008) Rapid strengthening of thalamo-amygdala synapses mediates cue-reward learning. Nature 453(7199):1253-1257.
189. Ungless MA, Singh V, Crowder TL, Yaka R, Ron D and Bonci A (2003) Corticotropin-releasing factor requires CRF binding protein to potentiate NMDA receptors via CRF receptor 2 in dopamine neurons. Neuron 39(3):401-407.
190. Ungless MA, Whistler JL, Malenka RC and Bonci A (2001) Single cocaine exposure in vivo induces long-term potentiation in dopamine neurons. Nature 411(6837):583-587.
191. Valdez GR, Zorrilla EP, Rivier J, Vale WW and Koob GF (2003) Locomotor suppressive and anxiolytic-like effects of urocortin 3, a highly selective type 2 corticotropin-releasing factor agonist. Brain Res 980(2):206-212.
192. Vale W, Spiess J, Rivier C and Rivier J (1981) Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 213(4514):1394-1397.
193. Van Pett K, Viau V, Bittencourt JC, Chan RK, Li HY, Arias C, Prins GS, Perrin M, Vale W and Sawchenko PE (2000) Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse. J Comp Neurol 428(2):191-212.
194. Vaughan J, Donaldson C, Bittencourt J, Perrin MH, Lewis K, Sutton S, Chan R, Turnbull AV, Lovejoy D, Rivier C and et al. (1995) Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 378(6554):287-292.
195. Veinante P, Stoeckel ME and Freund-Mercier MJ (1997) GABA- and peptide-immunoreactivities co-localize in the rat central extended amygdala. Neuroreport 8(13):2985-2989.
196. Vita N, Laurent P, Lefort S, Chalon P, Lelias JM, Kaghad M, Le Fur G, Caput D and Ferrara P (1993) Primary structure and functional expression of mouse pituitary and human brain corticotrophin releasing factor receptors. FEBS Lett 335(1):1-5.
197. Walker DL and Davis M (2008) Role of the extended amygdala in short-duration versus sustained fear: a tribute to Dr. Lennart Heimer. Brain Struct Funct 213(1-2):29-42.
198. Wallace BC (1989) Psychological and environmental determinants of relapse in crack cocaine smokers. J Subst Abuse Treat 6(2):95-106.
199. Wanat MJ, Hopf FW, Stuber GD, Phillips PE and Bonci A (2008) Corticotropin-releasing factor increases mouse ventral tegmental area dopamine neuron firing through a protein kinase C-dependent enhancement of Ih. J Physiol 586(8):2157-2170.
200. Wang B, You ZB, Rice KC and Wise RA (2007a) Stress-induced relapse to cocaine seeking: roles for the CRF(2) receptor and CRF-binding protein in the ventral tegmental area of the rat. Psychopharmacology (Berl) 193(2):283-294.
201. Wang H, Aodon g, Shu Y, Momotani Y, Wang X, Mori Y and Momotani E (2007b) Corticotropin-releasing hormone and urocortin expression in peripheral blood cells from experimentally infected cattle with Mycobacterium avium subsp. paratuberculosis. Microbes Infect 9(9):1061-1069.
202. Wang HL and Morales M (2008) Corticotropin-releasing factor binding protein within the ventral tegmental area is expressed in a subset of dopaminergic neurons. J Comp Neurol 509(3):302-318.
203. Wang J, Fang Q, Liu Z and Lu L (2006) Region-specific effects of brain corticotropin-releasing factor receptor type 1 blockade on footshock-stress- or drug-priming induced reinstatement of morphine conditioned place preference in rats. Psychopharmacology (Berl) 185(1):19-28.
204. Washburn MS and Moises HC (1992) Electrophysiological and morphological properties of rat basolateral amygdaloid neurons in vitro. J Neurosci 12(10):4066-4079.
205. Watkins SS, Epping-Jordan MP, Koob GF and Markou A (1999) Blockade of nicotine self-administration with nicotinic antagonists in rats. Pharmacol Biochem Behav 62(4):743-751.
206. Weiss F and Koob GF (2001) Drug addiction: functional neurotoxicity of the brain reward systems. Neurotox Res 3(1):145-156.
207. Wise RA (1978) Catecholamine theories of reward: a critical review. Brain Res 152(2):215-247.
208. Wise RA (1998) Drug-activation of brain reward pathways. Drug Alcohol Depend 51(12):13-22.
209. Wise RA (2005) Forebrain substrates of reward and motivation. J Comp Neurol 493(1):115-121.
210. Wise RA (2008) Dopamine and reward: the anhedonia hypothesis 30 years on. Neurotox Res 14(2-3):169-183.
211. Woods RJ, Kemp CF, David J and Lowry PJ (1997) Heterogeneity of the human corticotropin-releasing factor-binding protein. J Clin Endocrinol Metab 82(5):1566-1571.
212. Woods RJ, Kemp CF, David J, Sumner IG and Lowry PJ (1999) Cleavage of recombinant human corticotropin-releasing factor (CRF)-binding protein produces a 27-kilodalton fragment capable of binding CRF. J Clin Endocrinol Metab 84(8):2788-2794.
213. Wright SP, Doughty RN, Frampton CM, Gamble GD, Yandle TG and Richards AM (2009) Plasma urocortin 1 in human heart failure. Circ Heart Fail 2(5):465-471.
214. Xue Y, Steketee JD and Sun W (2012) Inactivation of the central nucleus of the amygdala reduces the effect of punishment on cocaine self-administration in rats. Eur J Neurosci 35(5):775-783.
215. Yamada Y, Mizutani K, Mizusawa Y, Hantani Y, Tanaka M, Tanaka Y, Tomimoto M, Sugawara M, Imai N, Yamada H, Okajima N and Haruta J (2004) New class of corticotropin-releasing factor (CRF) antagonists: small peptides having high binding affinity for CRF receptor. J Med Chem 47(5):1075-1078.
216. Yokel RA and Wise RA (1975) Increased lever pressing for amphetamine after pimozide in rats: implications for a dopamine theory of reward. Science 187(4176):547-549.
217. Zorrilla EP and Koob GF (2012) Progress in corticotropin-releasing factor-1 antagonist development. Drug Discov Today 15(9-10):371-383.
218. Zorrilla EP, Valdez GR and Weiss F (2001) Changes in levels of regional CRF-likeimmunoreactivity and plasma corticosterone during protracted drug withdrawal in dependent rats. Psychopharmacology (Berl) 158(4):374-381.